Minimal residual disease in autologous hematopoietic harvests from breast cancer patients

Annals of Oncology

Volumn 9, Issue 8, 1998, Pages 821-826

  Spyridonidis, A ^a   Bernhardt, W ^a   Fetscher, S ^a   Behringer, D ^a   Mertelsmann, R ^a   Henschler, R ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Breast cancer; High dose chemotherapy; Minimal residual disease; Stem cell transplantation

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; CD34 ANTIGEN; CYTOKERATIN 19; MAFOSFAMIDE; MONOCLONAL ANTIBODY;

AUTOGRAFT; BONE MARROW PURGING; BREAST CANCER; CELL SELECTION; CLINICAL TRIAL; GENE THERAPY; HUMAN; IMMUNOCYTOCHEMISTRY; MINIMAL RESIDUAL DISEASE; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; STEM CELL TRANSPLANTATION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; NEOPLASM, RESIDUAL; TREATMENT OUTCOME;

EID: 0031684669     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008344708061     Document Type: Review

References (72)

1. Antman KH, Rowlings PA, Vaughan WP et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 1997; 15: 1870-9.
2. Peters WP. High-dose chemotherapy with autologous bone marrow transplantation for the treatment of breast cancer. In DeVita VT, Rosenberg SA (eds): Important Advances in Oncology. Philadelphia: JB Lippincott 1995; 215-30.
3. Bezwoda WR, Seymour I, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial. J Clin Oncol 1995; 13: 2483-9.
4. Osborne MP, Rosen PP. Detection and management of bone marrow micrometastases in breast cancer. Oncology 1994; 8: 25-31.
5. Pantel K, Moss TJ. First International ISHAGE Symposium on Minimal Residual Cancer: Meeting report. J Hematother 1996; 5: 511-7.
6. Pantel K, Schlimok G, Angstwurm M et al. Methodological analysis of immunocytochemical screening for disseminated epithelial tumour cells in bone marrow. J Hematother 1994; 3: 165-73.
7. Theocharous P, Lowdell MW, Jones AL et al. Immunocytochemical detection of breast cancer cells: A comparison of three attachment factors. J Hematother 1997; 6: 21-9.
8. Mesker WE, Burg JM, Oud PS et al. Detection of immunocytochemically stained rare events using image analysis. Cytometry 1994; 17: 209-15.
9. Naume B, Borgen E, Beiske K et al. Immunomagnetic techniques for the enrichment and detection of isolated breast carcinoma cells in bone marrow and peripheral blood. J Hematother 1997; 6: 103-14.
10. Vredenburgh J, Silva O, Tyer C et al. A comparison of immunohistochemistry, two-color immunofluorescence, and flow cytometry with cell sorting for the detection of micrometastatic breast cancer in the bone marrow. J Hematother 1996; 5: 57-62.
11. Datta YH, Adams PD, Drobyski WR et al. Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. J Clin Oncol 1993; 12: 475-82.
12. Krismann M, Todt B, Schröder J et al. Low specifity of cytokeratin 19 reverse transcriptase-polymerase chain reaction analyses for detection of hematogenous lung cancer dissemination. J Clin Oncol 1995; 13: 2769-75.
13. Sharp JG, Bishop M, Chan WC et al. Detection of minimal residual diease in hematopoietic tissues. In Sackstein R, Janssen WE, Elfenbein GJ (eds): Annals of the New York Academy of Medicine. Vol. 770. New York: The New York Academy of Sciences 1995; 242-61.
14. Sharp JG. Micrometastases and transplantation. J Hematother 1996; 5: 519-24.
15. Mapara MY, Körner IJ, Hildebrandt M et al. Monitoring of tumor cell purging after highly efficient immunomagnetic selection of CD34 cells from leukapheresis products in breast cancer patients: Comparison of immunocytochemical tumor cell staining and reverse transcriptase-polymerase chain reaction. Blood 1997; 89: 337-44.
16. Sharp JG, Mann SL, Kessinger A et al. Detection of occult breast cancer cells in cultured pretransplantation bone marrow. In Dicke KA, Spitzer G, Jagannath S (eds): Autologous Bone Marrow Transplantation. Vol. III. Houston: The University of Texas, MD Anderson Cancer Center 1987; 497-502.
17. Sharp JG, Mann SL, Murphy B et al. Culture methods for the detection of minimal tumor contamination of hematopoietic harvests: A review. J Hematother 1995; 4: 141-8.
18. Greer G, Franklin W, Hami L et al. A clonogenic culture method for the identification of breast cancer cells in marrow aspirates of patients receiving high-dose chemotherapy. Blood 1996; 88 (Suppl 1): 252 (Abstr).
19. Ross AA, Cooper BW, Lazarus HM et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993; 82: 2605-10.
20. Brenner MK, Rill DR, Moen R C et al. Gene marking to trace origin of relapse after autologous bone marrow transplantation. Lancet 1993; 341: 85-6.
21. Rill DR, Santana VM, Roberts WM et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994; 84: 380-3.
22. Deisseroth AB, Zu Z, Claxton D et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow transplantation for CML. Blood 1994; 83: 3068-76.
23. Niederwie DW, Appelbaum FR, Gastl G et al. Inadvertent transmission of a donor's acute myeloid leukemia in bone marrow transplantation for chronic myelocytic leukemia. N Engl J Med 1990; 322: 1794-6.
24. Gribben JG, Freedman AS, Neuberg D et al. Immunologic purging of bone marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991; 325: 1525-33.
25. Rowley SD, Jones RJ, Piantadosi S et al. Efficacy of ex vivo purging for autologous bone marrow transplantation in the treatment of acute nonlymphoblastic leukemia. Blood 1989; 74: 501-6.
26. Gorin NC, Aegerter P, Auvert B et al. Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: A European survey of the role of marrow purging. Blood 1990; 75: 1606-14.
27. Sharp JG, Kessinger A, Mann S et al. Outcome of high-dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest. J Clin Oncol 1996; 14: 214-9.
28. Brockstein BE, Ross AA, Moss TJ et al. Tumor cell contamination of bone marrow harvest products: clinical consequences in a cohort of advanced-staged breast cancer patients undergoing high-dose chemotherapy (HDC). J Hematother 1996; 5: 617-24.
29. Berenson RJ, Shpall EJ, Franklin WA et al. Transplantation of CD34 positive marrow and/or peripheral blood progenitor cells into breast cancer patients following high-dose chemotherapy. BMT 1995; 15: 32 (Abstr).
30. Glück S, Ross AA, Goldstein L et al. Detection of breast cancer cells in the apheresis product and their potential clinical significance. Blood 1996; 88 (Suppl 1): 605 (Abstr).
31. Ybanez Y, Lazarus H, Ross A et al. Impact of occult tumor reinfusion on outcome after high-dose chemotherapy in patients with advanced breast cancer. Blood 1995; 86 (Suppl 1): 1532 (Abstr).
32. Vredenburgh J, Silva O, DeSombre K et al. The significance of bone marrow micrometastases for patients with breast cancer and > 10+ lymph nodes treated with high-dose chemotherapy and hematopoietic support. Proc Am Soc Clin Oncol 1995; 14: 317 (Abstr).
33. Schulze R, Schulze M, Wischnik A et al. Tumor cell contamination of peripheral blood stem cell transplants and bone marrow in high-risk breast cancer patients. BMT 1997; 19: 1223-8.
34. Kessinger A, Reed E, Vaughan W et al. Clinical outcome of patients with breast cancer and gynecological epithelial tumors undergoing high-dose therapy and peripheral blood stem cell transplantation with or without minimally contaminated apheresis harvests. Proc Am Soc Clin Oncol 1993; 12: 74 (Abstr).
35. Fields KK, Elfenbein GJ, Trudeau WL et al. Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation. J Clin Oncol 1996; 14: 1868-76.
36. Moreb J, Cooper B, Holland K et al. The prognostic value of immunocytochemical (ICC) analysis on bone marrow (BM) taken from patients with stage II-III breast cancer undergoing autologous transplant (ABMT) therapy. Blood 1997; 90: 1703 (Abstr).
37. Douer D, Levine A, Anderson WF et al. High-dose chemotherapy and autologous bone marrow plus peripheral blood stem cell transplantation for patients with lymphoma or metastatic breast cancer: Use of marker genes to investigate hematopoietic reconstitution in adults. Hum Gene Ther 1996; 7: 669-84.
38. Pantel K, Schlimok G, Kutter D et al. Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells. Cancer Res 1991; 51: 4712-5.
39. Pantel K, Angstwurm M, Kutter D. Down-regulation and neoexpression of cell surface antigens on individual micrometastatic carcinoma cells. In Rabes H, Peters PE, Munk K (eds): Metastasis: Basic Research and its Clinical Applications. Contributions to Oncology. Basel: Karger 1992; 283-93.
40. Pantel K, Schlimok G, Braun S et al. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 1993; 85: 1419-24.
41. Pantel K, Dickmans A, Zippelius A et al. Establishment of micrometastatic carcinoma cell lines: A novel source of tumor cell vaccines. J Natl Cancer Inst 1995; 87: 1162-8.
42. Mann SL, Joshi SS, Crouse DA et al. Increased hematopoietic progenitor cell maintenance in long term bone marrow cultures in the presence of contaminating tumor cells. Blood 1987; 70 (Suppl 1): 311 (Abstr).
43. Brugger W, Bross KJ, Glatt M et al. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994; 83: 636-40.
44. Ross AA, Layton TJ, Ostrander AB et al. Comparative analysis of breast cancer contamination in mobilized and nonmobilized hematopoietic grafts. J Hemather 1996; 5: 549-52.
45. Kvalheim G, Gilen B, Erikstein B et al. Detection of micrometastasis in bone marrow and blood in high-risk stage Il breast cancer patients. Blood 1997; 90: 948 (Abstr).
46. Berdel W, Danhauser-Riedl S, Steinhauser G et al. Various human hematopoietic growth factors (IL-3, GM-CSF, G-CSF) stimulate clonal growth of nonhematopoietic tumor cells. Blood 1989; 73: 80-3.
47. Pecora AL, Lazarus H, Cooper B et al. Breast cancer contamination in peripheral blood stem cell (PBSC) collections: Association with bone marrow disease and type of mobilization. Blood 1997; 90: 434 (Abstr).
48. Kahn DG, Prilutskaya M, Cooper B et al. The relationship between the incidence of tumor contamination and number of pheresis for stage IV breast cancer. Blood 1997; 90: 2514 (Abstr).
49. Shpall EJ, Jones RB, Bearman SI et al. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: Influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. J Clin Oncol 1994; 12: 28-36.
50. Kies MS, Gordon LI, Rosen ST et al. Autologous bone marrow transplantation in breast cancer: Separation of clonogenic tumor cell colonies by gradient fractionation. Exp Hematol 1988; 16: 190-4.
51. Morecki S, Pavlotzky F, Margel S et al. Purging breast cancer cells in preparation for autologous bone marrow transplantation. BMT 1987; 1: 357-63.
52. Dielzfelbinger HF, Kühn D, Zafferani M et al. Removal of breast cancer cells from bone marrow by in vitro purging with ether lipids and cryopreservation. Cancer Res 1993; 53: 3747-51.
53. Ingram SS, Samulski T, Dodge R et al. The effects of hyperthermia in bone marrow purging of breast cancer. Int J Hyperthermia 1996; 12: 21-9.
54. Dooley DC, Xiao M, Wickramasinghe SR et al. A novel, inexpesive technique for the removal of breast cancer cells from mobilized peripheral blood stem cell products. Blood 1996; 88 (Suppl 1): 252 (Abstr).
55. Shpall EJ, Jones RB, Bast RC et al. 4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: A phase I trial. J Clin Oncol 1991; 9: 85-93.
56. Passos-Coelho JL, Ross AA, Davis JM et al. Bone marrow micrometastases in chemotherapy-responsive advanced breast cancer: Effect of ex vivo purging with 4-hydroperoxycyclophosphamide. Cancer Res 1994; 54: 2366-71.
57. Seth P, Brinkmann U, Schwartz GN et al. Adenovirus-mediated gene transfer to human breast tumor cells: An approach for cancer gene therapy and bone marrow purging. Cancer Res 1996; 56: 1346-51.
58. Hirai M, Kelsey L, Qian F et al. optimal conditions for the adenovirus-p53 purging of breast cancer stem cell products. Blood 1997; 90: 949 (Abstr).
59. Vredenburgh JJ, Simpson W, Memoli VA et al. Reactivity of anti-CD15 monoclonal antibody PM-81 with breast cancer and elimination of breast cancer cells from human bone marrow by PM-81 and immunomagnetic beads. Cancer Res 1991; 51: 2451-5.
60. Myklebust AT, Godai A, Juell S et al. Comparison of two antibody-based methods for elimination of breast cancer cells from human bone marrow. Cancer Res 1994; 54: 209-14.
61. Coombes CR, Buckman R, Forrester A et al. In vitro and in vivo effects of a monoclonal antibody-toxin conjugate for use in autologous bone marrow transplantation for patients with breast cancer. Cancer Res 1986; 46: 4217-20.
62. Bjorn MJ, Manger R, Sivam G et al. Selective elimination of breast cancer cells from human bone marrow using an antibody-pseudomonas exotoxin A conjugate. Cancer Res 1990; 50: 5992-6.
63. Tondini C, Pap SA, Hayes DF et al. Evaluation of monoclonal antibody DF3 conjugated with ricin as a specific immunotoxin for in vitro purging of human bone marrow. Cancer Res 1990; 50: 1170-5.
64. O'Briant KC, Sphall EJ, Houston LL et al. Elimination of clonogenic breast cancer cells from human bone marrow. Cancer (Philadelphia) 1991; 68: 1272-8.
65. Brugger W, Heimfeld S, Berenson R et al. Ex vivo expanded peripheral blood CD34+ cells mediate hematopoietic recovery after high-dose chemotherapy. N Engl J Med 1995; 333: 283-7.
66. Vogel W, Behringer D, Scheding S et al. Ex vivo expansion of CD34+ peripheral blood progenitor cells: Implications for the expansion of contaminating epithelial tumor cells. Blood 1996; 88: 2707-13.
67. Ross AA, Loudovaris M, Hazelton B et al. Immunocytochemical analysis of tumor cells in pre- and post-culture peripheral blood progenitor cell collections from breast cancer patients. Exp Hematol 1995; 23: 1478-83.
68. Purdy MH, Hogan CJ, Hami L et al. Large volume ex vivo expansion of CD34-positive hematopoietic progenitor cells for transplantation. J Hematother 1995; 4: 515-25.
69. Lundell BI, Tyer C, DeSombre K et al. Ex vivo perfusion culture expansion of tumor positive bone marrow from breast cancer patients results in passive purging during the culture period. Blood 1997; 90: 951 (Abstr).
70. Spyridonidis A, Bernhardt W, Behringer D et al. Proliferation and survival of mammary carcinoma cells are influenced by culture conditions used for ex vivo expansion of CD34+ blood progenitor cells. Blood 1997; 90: 1873 (Abstr).
71. Spyridonidis A, Schmidt A, Bernhardt W et al. Purging of mammary carcinoma cells during ex vivo culture of CD34+ hematopoietic progenitor cells with recombinant immunotoxins. Blood 1998; 91: 1820-7.
72. Glück S, Ross AA, Layton T et al. Detection of breast cancer cells in the apheresis product: Potential clinical significance. Autologous marrow and blood transplantation. Arlington, TX 1997; 295-303.